Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.

@article{Rudolph2015SlowIA,
  title={Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.},
  author={Johannes Rudolph and Yao Xiao and Arthur Pardi and Natalie G Ahn},
  journal={Biochemistry},
  year={2015},
  volume={54 1},
  pages={22-31}
}
The mitogen-activated protein (MAP) kinase pathway is a target for anticancer therapy, validated using inhibitors of B-Raf and MAP kinase kinase (MKK) 1 and 2. Clinical outcomes show a high frequency of acquired resistance in patient tumors, involving upregulation of activity of the MAP kinase, extracellular signal-regulated kinase (ERK) 1 and 2. Thus… CONTINUE READING